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Robustiano Pego11†, Carmen Calles12†, César García-Rey13, Nuria Monsalve14 and David Sánchez-Matienzo14Abstract
Background: This study aimed to correlate body mass index or biomarkers with the frequency of common adverse
events (AEs) with subcutaneous IFN β-1a during treatment titration in patients with relapsing-remitting multiple
sclerosis previously naïve to IFN β.
Methods: Eighty-four patients (66.3% females) were followed up during 8 weeks, 25.3% were overweight and
14.5% were obese.
Results: Biomarkers steadily increased during all study period by 45.3% for β2-microglobulin, 262.8% for
olygoadenylate synthetase-1, and 92.8% for neopterin. Overall AE reporting did not vary with the dose or treatment
duration.
Conclusions: BMI was not predictive of increased risk for AEs. Biomarkers did not discriminate on the frequency of
any AE either.
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More than one decade ago, recombinant human inter-
feron β (IFN β) was the first approved disease modifying
drug, and still remains as a standard first-line therapy
for relapsing-remitting multiple sclerosis (RRMS).
When IFN β binds its receptors on the cell membrane,
it induces the secretion of proteins with antiviral,
antiproliferative and immunomodulator activities. β2-
microglobulin (β2M), 2’-5’-oligoadenylate synthethase-1
(OAS1) and neopterin (Np) are among the best known
pharmacodynamic biomarkers often used to assess the
IFN β biological activity [1-4] and these are usually* Correspondence: casanova_bon@gva.es
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reproduction in any medium, provided the orinversely correlated with the presence of anti-interferon
neutralizing antibodies [5-7].
The 2,5-oligoadenylate synthetase 1 (OAS 1) system is
an IFN-induced antiviral pathway, which confers pro-
tective and antiproliferative properties. When activated,
OAS proteins catalyse the polymerization of ATP into
2'-5'-linked oligomers. Some polymorphisms of OAS1
gene may confer susceptibility to develop multiple
sclerosis [8].
β2-microglobulin (β2MG) is associated with class I an-
tigens of the major histocompatibility complex on the
surface of lymphocytes and is considered to be a marker
for disease activity in some immune and neoplastic dis-
orders. Niezgoda et al. found a significant decrease in
cerebrospinal fluid and serum β2MG levels in MS pa-
tients after cladribine treatment, associated with a slight
but significant clinical improvement measured by EDSS
[9]. However, Bagnato et al. followed the evolution ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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any relationship between this marker and disease
activity [4].
Neopterin (Np) is synthesized by macrophages upon
stimulation with interferon and it is indicative of a pro-
inflammatory immune status. Np serves as a marker of
cellular immune system activation under the control of
T helper cells type 1. Elevated Np concentrations are
among the best predictors of adverse outcome in pa-
tients with HIV infection, in cardiovascular disease and
in various types of cancer [10]. Most studies however
have not found a clear correlation with multiple sclerosis
progression [3,11].
Patients with MS tend to be more overweight than the
general population [12] .Obesity seems to contribute to
a delay in the diagnosis of MS through a still undeter-
mined mechanism [13].
IFN-beta-1-a-induced immunomodulation in vivo de-
pends on the administration schedule being 2–3 times
greater the effect when a same weekly dose is divided in
three injections [14].
Indicators of treatment response or drug-related AEs,
either non-modifiable pharmacogenetic indicators like
polymorphisms of genes or pharmacodynamic markers
[15] might contribute to identify patients who can better
benefit from treatment.
Recently, a study showed differences between re-
sponders and non responders in the genes associated
with ion channels and signal transduction pathways.
This study also suggests that genetic variants in heparan
sulfate proteoglycan genes may be of clinical interest in
MS as predictors of the response to therapy [16] .So far,
no study has addressed a correlation of either body mass
index (BMI) or IFN β biomarkers with the frequency of
common AEs, which could help develop a more individ-
ualized IFN β therapy. The aim of the present clinical
trial was to address whether variations of BMI or phar-
macodynamic biomarkers are associated to different AE
profiles during the titration phase of IFN β-naïve pa-
tients with RRMS.
Methods
This interventional open-label, single arm trial (EudraCT
Number 2006-000606-23) was performed in 12 hospitals
in Spain from July 2008 to June 2010, and was approved
by all the Institutional Review Boards prior to initiation.
All patients signed an informed consent form before en-
rollment, and were included in the study if aged between
18 and 60 years, diagnosed with RRMS, had suffered
from one or more relapses within the previous 12
months, had an Expanded Disability Status Scale (EDSS)
score < 5.5, and had not been previously treated with
any IFN β or any other disease modifying drug (DMD).
Exclusion criteria included progressive forms of MS,current or past liver abnormal function, leukocytopenia
during the month prior to the start of the study, and
presence of any other systemic disease.
The study treatment was IFN β-1a (Rebif®, Merck
Serono), administered subcutaneously three times per
week, starting with a dose of 8.8 μg for 2 weeks, then in-
creasing up to 22 μg for other 2 weeks, and finally from
day 28 on, at the targeted dose of 44 μg. The study end
was after 56 days, following which patients were treated
based on normal physician’s practice. On days 1, 14, 28
and 56 blood samples were taken before the next admin-
istration of the study drug to perform a complete blood
cell count, analysis of liver and renal function, and also
determination of the three MS biomarkers: β2M was
measured by chemiluminescence (Immulite2000, Sie-
mens), Np by ELISA (DRG International) and OAS1 by
RIA (Izasa). Adverse event logs were documented at
each visit.
At the same time serum samples were stored frozen
at −70C until shipped to a central laboratory for the
determination of the three biomarkers β2 microglobulin,
neopterin and 2’-5’ oligoadenylate synthetase. β2
microglobulin was measured by chemiluminescence with
reagents provided by Siemens. Neopterin was assessed
by enzyme-linked immunosorbent assay (ELISA) using
DRG International reagents. 2’-5’ oligoadenylate synthe-
tase was determined by means of radioimmunoassay
with reagents from Izasa. An adverse event log was com-
pleted at each visit. The Student t-test for related and
unrelated samples was used to compare means as appro-
priate. The correlation between BMI, biomarkers and
lab results was also assessed using the Pearson or
Spearman coefficients (for variables of normal or non
parametric distribution according to the Kolmogorov-
Smirnov test). The significance level was set at 0.05.
The means of the biochemical, hematological and bio-
markers values will be compared to the baseline with a
Student-t test for related samples so as to assess the evo-
lution of these variables. The change in the biochemical,
hematological and biomarkers values was also compared
to the BMI by means of a scattergram and the Pearson
(for variables of normal distribution) or Spearman (for
non parametric variables) coefficients. The BMI mean of
patients with and without headache, influenza-like
syndrome and local toxicity with was compared with
Student-t test for unrelated samples.
Likewise, the relationship between both the basal value
of the three biomarkers and their change over time,
among patient with or without adverse events was
assessed with the Student-t test for unrelated samples.
As for the relation between biomarkers and biochemical
and hematological variables, their correlation by means
of the Pearson or Spearman coefficients was also
explored.
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level of the three biomarkers, adjusted by BMI, and their
association with the frequency of AEs. As a secondary
endpoint, we aimed to further study these three bio-
markers, adjusted by BMI, with the seriousness of AEs.Results and discussion
A total of 84 patients were enrolled in this study. One
patient was lost to follow up after first visit, and 83 pa-
tients completed the full study. Demographic character-
istics (mean and standard deviation (SD)) of study
population are summarized as follows: weight 70.7 kg
(17.0), height 166.3 cm (9.7), age 36.6 years (9.2), time
from diagnosis to treatment 16.4 days (4.0), baseline
EDSS 1.7 (1.0), 12 months before study EDSS (only
available for 33 patients) 0.9 (1.1) and BMI 25.5 kg/m
[2] (5.5). As for gender, female proportion was 66.3%.
60.2% of patients had normal BMI (< 25 kg/m2), 25.3%
were overweight (≥25 y < 30 kg/m2) and 14.5% were
obese (≥ 30 kg/m2). The proportion of relapses in the
previous 12 months before the study was 1 in 59.0% of
patients, 2 in 32.3% and 3 or more, in 9.6%.
Baseline and final 56-day mean values of the different
continuous variables studied are shown in Table 1.
Biomarkers also followed a significant (p < 0.01) and
steady increase at 56 days after treatment compared withTable 1 Basal and final means of biochemical, hematological
Variable Basal mean (SD)
[No. of Valid cases]
Final me
[No. of Va
Haemoglobin (g/dL) 13.94 (1.16) [81] 13.64 (1
Hematocrit (%) 41.48 (3.50) [81] 40.56 (3
Blood sedimentation rate
(mm)
12.31 (10.89) [58] 14.49 (11
Leukocytes
(1000/mm [3])
8.25 (3.14) [83] 5.67 (1.
Granulocytes
(1000/mm [3])
5.29 (2.88) [82] 3.20 (1.
Lymphocytes
(1000/mm [3])
2.32 (1.10) [83] 1.76 (0.
Platelet count
(1000/mm [3]
275.59 (81.21) [83] 211.39 (6
Creatinine 0.78 (0.17) [82] 0.74 (0.
sGOT (ALT) 17.50 (5.99) [80] 34.11 (39
sGPT (AST) 23.34 (15.66) [80] 53.56 (98
GGT 19.18 (11.23) [68] 36.34 (36
Alkaline phosphatase 95.54 (46.27) [67] 101.24 (4
Bilirubin 0.60 (.36) [78] 0.53 (0.
β2M 1.27 (0.23) [83] 1.84 (0.
OAS1 50.65 (45.04) [79] 183.75 (9
Np 1.46 (0.68) [83] 2.81 (0.
* Paired samples test for difference of means (2-tailed).baseline values: β2M increased by 45.3%, OAS1 by
262.8% and Np by 92.8%.
As most common AEs, influenza-like symptoms were
reported in 28 subjects (33.7%), headache in 15 (18.1%)
and local reactions at the injection site in 11 subjects
(13.3%). With regard to blood analysis, there were 8
cases of abnormal liver enzymes (9.6%), 4 cases of
leukocytopenia (4.8%) and one case of thrombocytopenia
(1.2%). Three (3.6%) patients were withdrawn from the
study, 2 of them at second visit on day 14, due to severe
chills and suicide thinking, respectively, and the third
patient at third visit on day 28 due to a severe increase
of transaminases.
Frequencies of AEs did not increase as the study
progressed, despite dose escalation. The overall propor-
tion of subjects reporting any AE was similar at each
study visit (39.5% on day 14, 42% on day 28, and 42% on
day 56).
No association between mean BMI and frequency of
total or any specific AE was established. Similarly, no
strong associations were found between BMI and
variations of studied biomarkers (all correlations were
under ±0,03). Additionally, no significant differences be-
tween either the mean baseline value or the variations
of biomarkers were found to be associated to patients
reporting any AE vs. those non reporting AEs (see







.28) [81] NS −0.015 0.095
.61) [81] NS −0.095 0.020
.65) [71] NS 0.112 0.067
67) [81] <0.01 −0.081 0.056
22) [81] <0.01 −0.127 0.014
61) [81] <0.01 −0.060 0.106
3.98) [81] <0.01 0.078 0.158
15) [81] 0.02 −0.117 −0.091
.75) [81] <0.01 −0.091 −0.149
.87) [81] <0.01 −0.149 −0.178
.93) [73] <0.01 −0.102 −0.008
8.73) [75] NS −0.037 −0148
30) [81] 0.025 0.084 0.049
26) [83] <0.01 −0.189 −0.259
9.52) [83] <0.01 0.003 −0.043
81) [83] <0.01 0.034 −0.043
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In conclusion, we found that BMI and pharmacody-
namic biomarkers were not predictive of an increased
frequency of AEs.
To our knowledge, these are the first results establishing
a lack of correlation between BMI or biomarkers with
frequency of AEs for IFN β-1a during the first two months
of treatment. Therefore, an individualized approach should
not be based on BMI or biomarkers from a safety
perspective.
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